tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Protoporphyria, Erythropoietic D046351 1 associated lipids
Colitis, Collagenous D046729 1 associated lipids
Hepatic Insufficiency D048550 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Dyslipidemias D050171 7 associated lipids
Atherosclerosis D050197 85 associated lipids
Granulomatosis, Orofacial D051261 2 associated lipids
Lymphohistiocytosis, Hemophagocytic D051359 1 associated lipids
Renal Insufficiency D051437 8 associated lipids
Delayed Graft Function D051799 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Galat A A note on circular-dichroic-constrained prediction of protein secondary structure. 1996 Eur. J. Biochem. pmid:8612612
Márquez JA and Serrano R Multiple transduction pathways regulate the sodium-extrusion gene PMR2/ENA1 during salt stress in yeast. 1996 FEBS Lett. pmid:8612770
Stoller G et al. An 11.8 kDa proteolytic fragment of the E. coli trigger factor represents the domain carrying the peptidyl-prolyl cis/trans isomerase activity. 1996 FEBS Lett. pmid:8612805
Kogi M et al. Effects of calyculin A and FK506 on the O2- generation of rat peritoneal macrophages. 1996 Tokai J. Exp. Clin. Med. pmid:9239803
Jin MB et al. Protective effect of FK 506 on hepatic energy metabolism in warm ischemic canine livers induced by total hepatic vascular exclusion. 1996 Transplant. Proc. pmid:8623243
Smit JA et al. Induction of primate TH2 lymphokines to suppress TH1 cells. 1996 Transplant. Proc. pmid:8623334
Tanaka M et al. Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. 1996 Transplant. Proc. pmid:8623341
Ye Q et al. Functional analysis of hamster kidney xenografts in the rat: possible functional incompatibility and adaptation of hamster kidney grafts in a xenogenic rat environment. 1996 Transplant. Proc. pmid:8623350
Namii Y et al. Tetrahydropyranyladriamycin with FK 506 combination therapy for hamster-to-rat-concordant xenotransplantation. 1996 Transplant. Proc. pmid:8623358
Valdivia LA et al. Prolonged survival of hearts obtained from chimeric donors in a mouse to rat xenotransplant model. 1996 Transplant. Proc. pmid:8623371
Wakizaka Y et al. Xenotransplantation of hamster liver into Gunn rats reserves congenital hyperbilirubinemia. 1996 Transplant. Proc. pmid:8623372
Pan F et al. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. 1996 Transplant. Proc. pmid:8623373
Fukushima N et al. Histological findings in heart grafts after orthotopic pig to baboon cardiac transplantation. 1996 Transplant. Proc. pmid:8623400
Appignani BA et al. Neuroimaging findings in patients on immunosuppressive therapy: experience with tacrolimus toxicity. 1996 AJR Am J Roentgenol pmid:8623651
Asfar S et al. Small bowel transplantation. A life-saving option for selected patients with intestinal failure. 1996 Dig. Dis. Sci. pmid:8625758
Fehr T et al. Antascomicins A, B, C, D and E. Novel FKBP12 binding compounds from a Micromonospora strain. 1996 J. Antibiot. pmid:8626235
Zhang BW et al. T cell responses in calcineurin A alpha-deficient mice. 1996 J. Exp. Med. pmid:8627154
Dragovich PS et al. Structure-based design of novel, urea-containing FKBP12 inhibitors. 1996 J. Med. Chem. pmid:8627611
Eberhard OK et al. How best to use tacrolimus (FK506) for treatment of steroid- and OKT3-resistant rejection after renal transplantation. 1996 Transplantation pmid:8629294
Millis JM et al. Tacrolimus for primary treatment of steroid-resistant hepatic allograft rejection. 1996 Transplantation pmid:8629298
Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. The European FK 506 Multicentre Psoriasis Study Group. 1996 Arch Dermatol pmid:8629845
Esquivel CO et al. Suggested guidelines for the use of tacrolimus in pediatric liver transplant patients. 1996 Transplantation pmid:8607198
Peters KP et al. The automatic search for ligand binding sites in proteins of known three-dimensional structure using only geometric criteria. 1996 J. Mol. Biol. pmid:8609611
Singh N et al. Pulmonary infections in liver transplant recipients receiving tacrolimus. Changing pattern of microbial etiologies. 1996 Transplantation pmid:8610349
Yanchar NL et al. Tacrolimus (FK506)--its effects on intestinal glucose transport. 1996 Transplantation pmid:8610392
Hariharan S et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. 1996 Transplantation pmid:8610411
Cacciarelli TV et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. 1996 Transplantation pmid:8610416
Osowski CL et al. Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. 1996 Transplantation pmid:8610430
Lu YF et al. FK506, a Ca2+/calmodulin-dependent phosphatase inhibitor, inhibits the induction of long-term potentiation in the rat hippocampus. 1996 Neurosci. Lett. pmid:8907327
Ye Q et al. Persistence of donor cells and incidence of graft-versus-host disease after simultaneous small bowel and bone marrow transplantation. 1996 Transplant. Proc. pmid:8907895
Walgenbach KJ et al. Increased presence of mast cells and interleukin-4 during chronic rejection of rat intestinal allografts. 1996 Transplant. Proc. pmid:8907896
Nüssler NC et al. CD8+ host cells infiltrate the intestinal mucosa after allogeneic small bowel transplantation even in the absence of acute rejection. 1996 Transplant. Proc. pmid:8907898
Wu J et al. Reversal of multidrug resistance by tacrolimus hydrate. 1996 Methods Find Exp Clin Pharmacol pmid:9121220
Perego C et al. Orthotopic liver-small bowel transplantation in pigs: study of immunologic parameters during therapy with FK 506-based immunosuppressive regimens. 1996 Transplant. Proc. pmid:8907908
Alessiani M et al. Combined FK 506 and mycophenolate mofetil immunosuppression prolongs survival after small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907922
Cohen DS et al. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy. 1996 Transplant. Proc. pmid:8907923
Becker G et al. Diltiazem minimizes tubular damage due to FK506-mediated nephrotoxicity following ischemia and reperfusion in rats. 1996 Transpl. Immunol. pmid:8762016
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Paus R et al. Hair growth control by immunosuppression. 1996 Arch. Dermatol. Res. pmid:8818191
Michel G et al. FK506 in the treatment of inflammatory skin disease: promises and perspectives. 1996 Immunol. Today pmid:8820265
Boeve BF et al. Dysarthria and apraxia of speech associated with FK-506 (tacrolimus). 1996 Mayo Clin. Proc. pmid:8820772
Komatsu K et al. Prolonged survival of hamster-to-rat pulmonary xenografts by tacrolimus (FK506) and cyclophosphamide. 1996 J. Heart Lung Transplant. pmid:8820789
Hayashi K et al. Suppression of experimental crescentic-type anti-glomerular basement membrane (GBM) nephritis by FK506 (tacrolimus hydrate) in rats. 1996 Jpn. J. Pharmacol. pmid:8822088
Sasahara Y et al. Okadaic acid suppresses neural differentiation-dependent expression of the neurofilament-L gene in P19 embryonal carcinoma cells by post-transcriptional modification. 1996 J. Biol. Chem. pmid:8824230
Woodle ES et al. Tacrolimus therapy for refractory acute renal allograft rejection: a prospective multicenter trial. Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplant. Proc. pmid:8962225
Scott-Douglas N et al. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy. 1996 Transplant. Proc. pmid:8962226
Kliem V et al. FK 506 in the treatment of steroid- and OKT3-resistant rejection in renal transplant recipients: reduced dosage and anti-infective prophylaxis. 1996 Transplant. Proc. pmid:8962227
Becker G et al. Tacrolimus (FK 506) therapy in simultaneous pancreas kidney transplantation. 1996 Transplant. Proc. pmid:8962228
Kiuchi T et al. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects. 1996 Transplant. Proc. pmid:8962229
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Braun F et al. Clinical relevance of monitoring tacrolimus: comparison of microparticle enzyme immunoassay, enzyme-linked immunosorbent assay, and liquid chromatography mass spectrometry in renal transplant recipients converted from cyclosporine to tacrolimus. 1996 Transplant. Proc. pmid:8962231
Michel G et al. Antioncogene P53 and mitogenic cytokine interleukin-8 aberrantly expressed in psoriatic skin are inversely regulated by the antipsoriatic drug tacrolimus (FK506). 1996 Biochem. Pharmacol. pmid:8787547
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Gonschior AK et al. Tacrolimus (FK506) metabolite patterns in blood from liver and kidney transplant patients. 1996 Clin. Chem. pmid:8787699
Ikebe S et al. Immunosuppressive effect of tacrolimus (FK-506). Bone xenografts in rabbits. 1996 Acta Orthop Scand pmid:8792745
Masaki Y et al. Microchimerism and rat small bowel transplantation combined with donor-type bone marrow cells. 1996 Transplant. Proc. pmid:8769154
Jordan ML et al. Tacrolimus rescue therapy for renal transplant rejection. 1996 Transplant. Proc. pmid:8769174
Baruch Y et al. Anasarca and hypertrophic cardiomyopathy in a liver transplant patient on FK506: relieved after a switch to Neoral. 1996 Transplant. Proc. pmid:8769215
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Karashima T et al. FK506 and cyclosporin A inhibit growth factor-stimulated human keratinocyte proliferation by blocking cells in the G0/G1 phases of the cell cycle. 1996 J. Dermatol. Sci. pmid:8884530
Monfar M and Blenis J Inhibition of p70/p85 S6 kinase activities in T cells by dexamethasone. 1996 Mol. Endocrinol. pmid:8885245
Andoh TF et al. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. 1996 Kidney Int. pmid:8887267
Shapiro R et al. "Suboptimal" kidney donors: the experience with tacrolimus-based immunosuppression. 1996 Transplantation pmid:8932264
Mysliwiec J et al. The effect of tacrolimus (FK506) and cyclosporin A (CyA) on peripheral serotonergic mechanisms in uremic rats. 1996 Thromb. Res. pmid:8837316
Devlin J and Williams R Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. 1996 Transplantation pmid:8932266
Lamb GD and Stephenson DG Effects of FK506 and rapamycin on excitation-contraction coupling in skeletal muscle fibres of the rat. 1996 J. Physiol. (Lond.) pmid:8842013
Curran CF et al. Acute overdoses of tacrolimus. 1996 Transplantation pmid:8932293
Tanaka K et al. Effect of cyclosporin analogues and FK506 on transcellular transport of daunorubicin and vinblastine via P-glycoprotein. 1996 Pharm. Res. pmid:8842048
Bader A et al. Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry. 1996 Naunyn Schmiedebergs Arch. Pharmacol. pmid:8935714
Borvak J et al. The use of cyclosporine, FK506, and SDZ NIM811 to prevent CD25- quiescent peripheral blood mononuclear cells from producing human immunodeficiency virus. 1996 J. Infect. Dis. pmid:8843228
Galat A A large-scale processing of kinetic data files with derivation of the inhibitory constant Ki: an application to proline isomerases. 1996 Comput. Chem. pmid:8936426
Kawabe A et al. Anti-adhesion (anti-ICAM-1 and anti-LFA-1) therapy in a rat pancreas transplantation model. 1996 Transplant. Proc. pmid:8658893
Hayakawa K et al. Maintenance of unresponsiveness by short-term pulse therapy with FK 506 in rat transplantation. 1996 Transplant. Proc. pmid:8658904
Ishikawa M et al. Acetaminophen absorption test as a useful indicator of small intestinal rejection in rats. 1996 Transplant. Proc. pmid:8658911
Kawano K et al. FK506 reduces oxidative hepatic injury following cold ischemic preservation and transplantation. 1996 Transplant. Proc. pmid:8658938
Kanzler S et al. Complete reversal of FK 506 induced diabetes in a liver transplant recipient by change of immunosuppression to cyclosporine A. 1996 Z Gastroenterol pmid:8659188
Schaefer A et al. Ca2+/calmodulin-dependent and -independent down-regulation of c-myb mRNA levels in erythropoietin-responsive murine erythroleukemia cells. The role of calcineurin. 1996 J. Biol. Chem. pmid:8662717
Owens-Grillo JK et al. A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains. 1996 J. Biol. Chem. pmid:8662874
Kralli A and Yamamoto KR An FK506-sensitive transporter selectively decreases intracellular levels and potency of steroid hormones. 1996 J. Biol. Chem. pmid:8663352
Okada K et al. Effect of FK 506 administered topically versus intramuscularly on suppression of the corneal immune reaction in rats. 1996 Ophthalmologica pmid:8738464
Cox KL and Freese DK Tacrolimus (FK506): the pros and cons of its use as an immunosuppressant in pediatric liver transplantation. 1996 Clin Invest Med pmid:8889279
Bridges ND et al. Lung transplantation in infancy and early childhood. 1996 J. Heart Lung Transplant. pmid:8889985
Iwasaki K et al. Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid. 1996 Res. Commun. Mol. Pathol. Pharmacol. pmid:9029671
Bousvaros A et al. Tacrolimus (FK-506) treatment of fulminant colitis in a child. 1996 J. Pediatr. Gastroenterol. Nutr. pmid:8890089
De Rie MA et al. Soluble interleukin-2 receptor (sIL-2R) is a marker of disease activity in psoriasis: a comparison of sIL-2R, sCD27, sCD4, sCD8 and sICAM-1. 1996 Acta Derm. Venereol. pmid:8891007
Timmerman LA et al. Rapid shuttling of NF-AT in discrimination of Ca2+ signals and immunosuppression. 1996 Nature pmid:8893011
Inutsuka K et al. Reconstruction of trachea and carina with immediate or cryopreserved allografts in dogs. 1996 Ann. Thorac. Surg. pmid:8893587
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Ezeamuzie CI Anti-allergic activity of cyclosporin-A metabolites and their interaction with the parent compound and FK 506. 1996 Int. J. Immunopharmacol. pmid:8894806
Hemenway CS and Heitman J Immunosuppressant target protein FKBP12 is required for P-glycoprotein function in yeast. 1996 J. Biol. Chem. pmid:8702500
Tyedmers J et al. Efficient folding of firefly luciferase after transport into mammalian microsomes in the absence of luminal chaperones and folding catalysts. 1996 J. Biol. Chem. pmid:8702642
Raufman JP et al. Calcineurin mediates calcium-induced potentiation of adenylyl cyclase activity in dispersed chief cells from guinea pig stomach. Further evidence for cross-talk between signal transduction pathways that regulate pepsinogen secretion. 1996 J. Biol. Chem. pmid:8702699
Timerman AP et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. 1996 J. Biol. Chem. pmid:8702774
Shih M and Malbon CC Protein kinase C deficiency blocks recovery from agonist-induced desensitization. 1996 J. Biol. Chem. pmid:8702931
Okadome T et al. Characterization of the interaction of FKBP12 with the transforming growth factor-beta type I receptor in vivo. 1996 J. Biol. Chem. pmid:8702959
Rahfeld JU et al. Isolation and amino acid sequence of a new 22-kDa FKBP-like peptidyl-prolyl cis/trans-isomerase of Escherichia coli. Similarity to Mip-like proteins of pathogenic bacteria. 1996 J. Biol. Chem. pmid:8703024
Eckert B et al. Calcium-mobilizing insulin secretagogues stimulate transcription that is directed by the cyclic adenosine 3',5'-monophosphate/calcium response element in a pancreatic islet beta-cell line. 1996 Endocrinology pmid:8536617
Wesselborg S et al. Identification of a physical interaction between calcineurin and nuclear factor of activated T cells (NFATp). 1996 J. Biol. Chem. pmid:8576111
Furth S et al. Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. 1996 Pediatr. Nephrol. pmid:8611359
Brousse N and Goulet O Small bowel transplantation. 1996 BMJ pmid:8611766